Core Insights - Artiva Biotherapeutics announced promising long-term Phase 1/2 data for AlloNK® in treating relapsed/refractory B-cell non-Hodgkin lymphoma, highlighting prolonged duration of response, deep B-cell depletion, and a well-tolerated safety profile when combined with rituximab [1][4] - The company will present additional data on the scalability and consistency of the AlloNK manufacturing process at the upcoming ASGCT 28th Annual Meeting [2][3] Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing effective, safe, and accessible cell therapies for autoimmune diseases and cancers [4] - The lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies [4] - Artiva's pipeline includes CAR-NK candidates targeting both solid and hematologic cancers, with ongoing clinical trials for systemic lupus erythematosus and other autoimmune indications [4] Presentation Details - The company will present two abstracts at the ASGCT 28th Annual Meeting: - Abstract 858 on AlloNK Cell Therapy ± Rituximab on May 13, 2025 [3] - Abstract 1765 on the scalability and consistency of AlloNK on May 15, 2025 [3]
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting